Literature DB >> 7265179

Further studies on C9 deficiency.

H Kitamura, K Nagaki, S Inai.   

Abstract

Further studies were carried out on the C9 deficiency (C9D). Her serum complement activity (CH50) was 15.7 units when assayed in high ionic strength buffer and 8.8 or less than 5.0 units when assayed in low ionic strength buffer containing glucose or sucrose, respectively. It was revealed that this buffer-dependent CH50 variation of C9D serum was due to the effect of the buffer on the spontaneous lysis of EAC1-8. The serum bactericidal activity of C9D was low, but the addition of specific antibody against bacteria increased the activity indicating an important role of antibody in the serum bactericidal activity. Neither C9 inactivator(s) nor antibody against C9 was detected in the serum, indicating that the case had a defect of C9 synthesis. However, the estimation of C9 levels in the sera of her family could not reveal the mode of inheritance of C9D.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7265179

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  6 in total

1.  C9 deficiency in a patient with poststreptococcal glomerulonephritis.

Authors:  K Maruyama; H Arai; T Ogawa; M Hoshino; S Tomizawa; A Morikawa
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

2.  The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.

Authors:  H Kitamura; M Tsuboi; K Nagaki
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

3.  Study on C3-like factor in the serum of a C3-deficient subject.

Authors:  H Kitamura; H Nishimukai; Y Sano; K Nagaki
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

4.  Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.

Authors:  H Kitamura; M Tsuboi
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

5.  SLE-like and sicca symptoms in late component (C9) complement deficiency.

Authors:  M Sugimoto; M Nishikai; A Sato; Y Suzuki; M Nihei; J Uchida; N Mimura
Journal:  Ann Rheum Dis       Date:  1987-02       Impact factor: 19.103

6.  Hemolysis of human erythrocytes is a new bioactivity of gangliosides.

Authors:  K Horikawa; H Nakakuma; S Nagakura; M Kawakita; T Kagimoto; M Iwamori; Y Nagai; T Abe; K Takatsuki
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.